-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

Benzinga·11/06/2026 14:40:45
Listen to the news
Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.